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Background: Post-diagnosis weight gain in breast cancer patients has been associated with increased cancer recurrence and
mortality. Our study was designed to identify risk factors for this weight gain and create a predictive model to identify a high-risk
population for targeted interventions.
Methods: Chart review was conducted on 459 breast cancer patients from Northwestern Robert H. Lurie Cancer Centre to obtain
weights and body mass indices (BMIs) over an 18-month period from diagnosis. We also recorded tumour characteristics,
demographics, clinical factors, and treatment regimens. Blood samples were genotyped for 14 single-nucleotide polymorphisms
(SNPs) in fat mass and obesity-associated protein (FTO) and adiponectin pathway genes (ADIPOQ and ADIPOR1).
Results: In all, 56% of patients had 40.5kgm
–2 increase in BMI from diagnosis to 18 months, with average BMI and weight gain of
1.9kgm
–2 and 5.1kg, respectively. Our best predictive model was a primarily SNP-based model incorporating all 14 FTO and
adiponectin pathway SNPs studied, their epistatic interactions, and age and BMI at diagnosis, with area under receiver operating
characteristic curve of 0.85 for 18-month weight gain.
Conclusion: We created a powerful risk prediction model that can identify breast cancer patients at high risk for weight gain.
In contrast to other malignancies, many patients diagnosed with
breast cancer gain weight after diagnosis. A recent review
of the literature from 1997 to 2009 showed that 34%–100% of
patients gained weight post-diagnosis, and mean weight gain
ranged from 0.27 to 7.3kg over follow-up period ranging from 6
months to 5 years (Vance et al, 2011), values that are higher than
in the general population (Williamson et al, 1991; Williamson,
1993). This is especially significant in the breast cancer population
as obesity at diagnosis (Chlebowski et al, 2002; Kroenke et al, 2005;
Loi et al, 2005; Litton et al, 2008; Vance et al, 2011) and weight
gain after diagnosis (Camoriano et al, 1990; Chlebowski et al, 2002;
Kroenke et al, 2005) have both been shown to be associated
with poor prognosis, including increased cancer recurrence,
decreased overall and breast cancer-associated survival, and
decreased response to chemotherapy in addition to decreased
quality of life.
Studies have shown an association of clinical variables with this
weight gain, including baseline age and body mass index (BMI),
treatment factors such as chemotherapy and hormone therapy,
tumour characteristics such as stage, and menopausal status, but
with conflicting findings (Camoriano et al, 1990; Kumar et al,
1997; Demark-Wahnefried et al, 1997a,b; Aslani et al, 1999;
Day et al, 1999; Goodwin et al, 1999; Kutynec et al, 1999; Costa
et al, 2002; Lankester et al, 2002; Rock and Demark-Wahnefried,
2002; Freedman et al, 2004; Ingram and Brown, 2004; Irwin et al,
2005; Kroenke et al, 2005; Caan et al, 2006; Campbell et al, 2007;
Saquib et al, 2007; Han et al, 2009; Heideman et al, 2009; Gu et al,
2010). In the general population, there is an important genetic
background that contributes to obesity and weight gain (Fox et al,
2005; Silventoinen and Kaprio, 2009). FTO, fat mass and obesity-
associated protein, was recently found in genome-wide association
studies (GWAS) to be associated with obesity and is a protein
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thought to mediate its effect on weight by decreasing satiety and
activity levels (Hinney et al, 2007; Rampersaud et al, 2008; Wardle
et al, 2008). We previously published a case–control study showing
that FTO is expressed in both normal and malignant breast tissue
and that FTO polymorphisms are associated with breast cancer risk
(Kaklamani et al, 2011a). Adiponectin is an endogenous insulin
sensitiser that regulates the secretion of insulin-like growth factor,
oestrogens, and tumour necrosis factor, and along with its
receptors has also been shown to be associated with weight gain
as well as diabetes and cardiovascular disease (Menzaghi et al,
2002; Stumvoll et al, 2002; Ukkola et al, 2005; Yang and Chuang,
2006; Loos et al, 2007; Edwards et al, 2012). We have also
previously published data linking polymorphisms in the adipo-
nectin gene (ADIPOQ) and its receptor (ADIPOR1) to breast
cancer risk (Kaklamani et al, 2008a). To our knowledge, no studies
have investigated the effects of genetic variables on weight gain
after breast cancer diagnosis.
The purpose of our study is to investigate the contribution
to post-diagnosis weight gain of genetic polymorphisms in
FTO, ADIPOQ, and ADIPOR1, clinical variables, and gene 
environment interactions in breast cancer patients. By developing
and comparing various predictive models, we aim to create a risk
prediction tool that can be used clinically to isolate a high-risk
patient population for targeted weight loss interventions.
MATERIALS AND METHODS
Study participants. Patients were recruited from the medical
oncology clinics at Robert H Lurie Comprehensive Cancer Centre
from August 2007 to December 2009. All patients signed an
informed consent for study participation and for genetic studies,
and the protocol was approved by the Institutional Review Board
of Northwestern University. Inclusion criteria included diagnosis
of stages I–III breast cancer, age X18 years, and female
sex. Exclusion criteria included presence of in situ only cancer,
metastatic disease, pregnancy, or poorly controlled diseases that
can independently results in weight changes such as thyroid disease
or systemic infection.
Chart review. A retrospective chart review was conducted on
recruited patients to obtain weights and BMIs over an 18-month
period from diagnosis, tumour characteristics (ER/PR/HER2
status, grade, presence of lymph node metastases, stage), demo-
graphics (age, race), clinical factors (menopausal status), treatment
regimens (chemotherapy use and type, endocrine therapy use and
type, radiation use), family history of breast or ovarian cancer,
and any evidence of recurrence. Anthropometric variables
were measured in our outpatient clinic by trained staff. If weights
were not available within 2 months of the desired time point, data
were recorded as missing.
DNA isolation. Blood samples were collected for genotyping of
polymorphisms in FTO, ADIPOQ, and ADIPOR1. DNA from
whole blood lymphocytes was extracted using the QIAamp DNA
Blood Mini Kit (Qiagen, Hilden, Germany) and was stored
at  201C until use for genotyping.
Selection of SNPs. ADIPOQ has 410 single-nucleotide poly-
morphisms (SNPs; Hara et al, 2002; Vasseur et al, 2002) and two
linkage disequilibrium (LD) blocks with a block boundary between
 2049 and  450 (Menzaghi et al, 2002). We selected to genotype
haplotype tagging SNPs rs266729 (50 flanking region), rs822396
(intron 1), and rs822395 (intron 1) to tag block 1 and rs150129
(exon 2) and rs2241766 (intron 2) to tag block 2 as these are the
five most common SNPs and have been studied more extensively
by others as to their functionality and relation to diseases such as
diabetes mellitus (Hara et al, 2002; Menzaghi et al, 2002; Filippi
et al, 2005; Heid et al, 2006). ADIPOR1 has 428 SNPs and two LD
blocks (Soccio et al, 2006). One block extends from the 50 flanking
region to intron 4 and the other is located at the 30 end of the gene.
Based on this, we selected five common haplotype tagging SNPs for
genotyping. For block 1, we selected the following tagging
SNPs: rss2232853 (50 flanking region), rs12733285 (intron 1),
and rs134238 (intron 4). For block 2, we selected rs7539542 (exon
8) and rs10920531 (30 flanking region). These SNPs were selected
because they correspond to both LD blocks. All selected SNPs have
been previously studied in relation to breast cancer risk by our
group (Kaklamani et al, 2008a).
We selected four SNPs in FTO to evaluate. These SNPs were
selected based on previous data from GWAS (Hinney et al, 2007;
Grant et al, 2008; Thorleifsson et al, 2009) as well as our own
published data on their association with breast cancer risk
(Kaklamani et al, 2011a). More specifically, rs9939609 has been
previously identified to be significantly associated with obesity and
diabetes mellitus (Grant et al, 2008; van Hoek et al, 2008;
Thorleifsson et al, 2009; Zhao et al, 2009). Furthermore, other
SNPs in the same LD block (rs1121980, rs9939973, rs7193144,
rs9940128, and rs8050136) were found to be associated with
obesity (Hinney et al, 2007). The SNPs we selected to evaluate are
all in intron 1 of FTO and represent LD block 6 (rs7206790 and
rs8047395) and LD block 7 (rs9939609 and rs1477196).
Genotyping. Genotyping for the 14 SNPs was performed by
Taqman SNP allelic discrimination by means of an ABI 7900HT
(Applied Biosystems, Forest City, CA, USA). Results were
ascertained by using the SDS software version 2.3 (Applied
Biosystems). All results were automatically called (i.e., the device
displays the genotypes automatically with a 95% certainty). A total
of 5% of samples were genotyped in duplicate and showed 100%
concordance. A total of 31 of the 459 patients had missing blood
samples so these patients were not included in the genetic analyses.
Statistical analysis. Data were first analysed descriptively to
determine whether or not any missing values and outliers exist.
Hardy–Weinberg equilibrium was checked for each SNP. Genera-
lised linear models were implemented to explore the relationship
between the weight change and SNPs or covariates, both in a single-
SNP or single-covariate analysis and in a multiple-SNP analysis.
In the multiple-SNP analysis, we considered an epistatic model
in which the main effects of SNPs as well as their possible epistatic
interactions were fitted in the model. The purpose of including
epistatic interactions in a model is to understand how the effect of
a SNP depends on the presence or absence of another SNP, and to
aid discovery of some SNPs that affect the weight change mainly
through their epistatic effects. For both the single-SNP and
multiple-SNP analyses, we studied the influence of SNPs on the
weight change adjusted for the covariates that are statistically
significant in the single-covariate analysis.
To facilitate the analysis of epistatic interactions in a model, we
used the Cockerham genetic model to encode the main effects of
SNPs. We denoted the common homozygote (i.e., the homozygote
of a SNP with a higher frequency), heterozygote, and rare
homozygote for each SNP by c, h, and r, respectively. The
Cockerham model defines two main effects for each SNP, an
additive contrast as  1, 0, and 1 for c, h, and r, and a dominance
contrast as  0.5 for c and r and 0.5 for h, respectively (Cordell,
2002; Kao and Zeng, 2002). The additive effect represents
the genotypic effect (r–c)/2, and the dominance effect measures
h–(cþr)/2 in the probability of being cases. A positive additive
effect indicates that the rare homozygote increases the possibility of
weight change compared with the common homozygote, and a
positive dominance effect means that the heterozygote increases
the possibility of weight change compared with the mean of two
homozygotes. Accordingly, the epistatic predictors are constructed
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introducing four epistatic interactions for a pair of SNPs, that is,
additive–additive, additive–dominance, dominance–additive, and
dominance–dominance interactions.
For the covariates, we encoded binary exposure as 0 and 1, and
standardised other exposures to have a mean of 0 and a s.d. of
0.5. This scaling scheme puts continuous variables on the same
scale as symmetric binary variables.
We used the Bayesian hierarchical normal linear model (Lake
et al, 2003; Becker et al, 2005; Kwee et al, 2007; Hein et al, 2009)
because the classical normal linear models have problems such as
nonidentifiability of parameters, computational inefficiency, and
limited statistical power for detecting causal variants when there
are a large number of genetic factors and interactions, even if
highly correlated (Lake et al, 2003; Becker et al, 2005; Kwee et al,
2007; Hein et al, 2009). This Bayesian model can overcome these
problems mainly by placing some appropriate prior distributions
on parameters. Specifically, we assume independent Student’s t
priors, tnjð0;s2
j Þ, on parameters in the model. We are motivated to
use the t distribution because it can produce robust inference,
shrinkage estimation, and easy computation (Gelman et al, 2008;
Yi and Xu, 2008; Yi and Banerjee, 2009). The t distribution can be
expressed as a mixture of normal distributions with mean 0 and
variance distributed as scaled inverse-w2
bj j t2
j   Nð0;t2
j Þ; t2
j s2
j
     Inv   w2ðnj;s2
j Þ; j ¼ 1; ...;J;
where J is the total number of parameters and bj is the
jth parameter in the model, and the hyperparameters nj and
sj can be predetermined reasonably. For the main effects,
we set ðnj;sjÞ¼ð 1;2:5Þ. For epistatic interactions, we set
ðnj;sjÞ¼ð 1;2:5kG=kGGÞ, where kG and kGG are the total numbers
of main and epistatic interaction effects of SNPs, respectively.
These priors apply more stringent restrictions on interactions. We
fitted our hierarchical normal linear models by incorporating an
expectation-maximisation algorithm into the usual iteratively
weighted least squares for classical normal linear models.
To explore the factors that influence the higher and lower BMI
changes, we conducted a quartile analysis. To this end, we first
divided BMI change into four equal groups and select a sub-data
set in which the patients have BMI change in the lower (p25%)
and upper (X75%) quartiles. We then encoded BMI change in the
lower quartile as 0 and the upper quartile as 1. Given this data, we
re-run the statistical analyses described above and used odds ratio
(OR) to measure the effect sizes of SNPs and covariates of interest
on the BMI change.
To make model selection and interpretation of results more
proper, we compared and contrasted the deviance and the Akaike
information criterion (AIC) between different models. The
deviance, defined as  2 times the log-likelihood, is a measure of
goodness of fit; smaller deviance means better fit to data. AIC,
defined as deviance plus 2 times the number of predictors,
measures the predictive power; a model is estimated to reduce out-
of-sample prediction error if AIC decreases.
To assess the predictive accuracy of our models for weight gain,
we performed receiver operating characteristics (ROCs) analysis,
including estimation of true-positive rate (also known as
sensitivity) and false-positive rate (i.e., 1 – specificity), estimation
of an ROC curve, and computing the area under the ROC curve
(AUC). We conducted the analysis based on the two models: main
effect model and epistatic model.
RESULTS
Baseline characteristics. Of the 562 patients initially enrolled in
the study, 459 had adequate data to be included in our analysis. Of
the 103 patients who were not included in the analysis, only 5 were
lost to follow-up. Twenty-seven of the patients not included met
exclusion criteria that were missed on initial recruitment: 15 had
metastatic cancer, 5 had ductal carcinoma in situ, 2 had lobular
carcinoma in situ, 3 were pregnant, and 2 had a concurrent
malignancy. The remaining patients had missing weight data either
at baseline or on follow-up that precluded data analysis.
Table 1 highlights the baseline patient characteristics and
Table 2 the treatment characteristics of the 459 patients included in
our analyses. The average patient age was 51.3 (s.d. 10.9) years old
with the majority being Caucasian (74.5%) and the most common
minority population being African American. The mean baseline
BMI was 27.5kgm
–2, classified in the overweight category, and
mean baseline weight 74.2kg. About 70% of the patients received
chemotherapy and radiation therapy, with the most common
chemotherapy regimen being doxorubicin at 60mgm
–2 and
cyclophosphamide at 600mgm
–2 i.v. every 2 weeks for four cycles
followed by paclitaxel at 175mgm
–2 every 2 weeks for four cycles
(ddACT), and 78% received endocrine therapy with tamoxifen
being the most commonly used agent. Supplementary Table 1
shows the distribution of SNP alleles for the 4 FTO and
10 adiponectin pathway polymorphisms being evaluated in this
study along with allele frequencies. In all, o1% of the SNP data are
listed as undetermined, indicating that the analyser was unable to
determine the specific allele; each of these samples was run twice
for confirmation.
Weight gain. As seen in Table 3, 33% of patients at 6 months and
56% at 18 months had a BMI increase of 40.5kgm
–2 from
baseline. Average weight gain among these patients was 3.5kg
(s.d. 2.36kg) at 6 month and 5.1kg (s.d. 3.76kg) at 18-month
follow-up, with corresponding BMI increases from 1.3kgm
–2
(s.d. 0.84kgm
–2) to 1.9kgm
–2 (s.d. 1.42kgm
–2). To better evaluate
clinically significant weight gain, we looked at 45% increase in
baseline BMI and found that 13% of patients at 6 months and 36%
at 18 months had gained this amount of weight. The maximum
BMI increase was 9kgm
–2 at 18 months (38% increase in BMI),
with maximum weight increase of 23.4kg.
Univariate analysis of clinical variables. Supplementary Table 2
shows the significant clinical variables in the univariate analysis at
each time point of 6, 12, and 18 months from breast cancer
diagnosis. Results for our analyses are expressed in effect sizes, with
each value quantifying the relative change in BMI with variable of
interest, for example  0.106 for BMI at diagnosis indicating that
each additional increase in BMI by 1kgm
–2 at diagnosis is
associated with 0.106kgm
–2 less increase in BMI by 6 months.
Quartile analysis data is also included and expressed as ORs
comparing likelihood of being in the upper quartile of weight gain
compared with lower quartile with variable of interest. Results
show that BMI at diagnosis and age were both negatively correlated
with weight gain with younger and lower weight patients being at
higher risk of weight gain. Weight gain was also associated with
lower stage, ER/PR-positive markers, use of endocrine therapy, and
absence of chemotherapy. Among the chemotherapy regimens,
docetaxel 75mgm
–2 and cyclophosphamide 600mgm
–2 (TC) i.v.
every 3 weeks for four cycles was associated with less weight gain.
There was some support for weight gain with premenopausal
status at diagnosis (weight gain associated with premenopausal4
postmenopausal4perimenopausal), menopausal change from
premenopausal to peri/postmenopausal, absence of lymph node
metastases, lower tumour grade, tamoxifen use, and white race
though results were not significant across all time points. It should
be noted that menopause classification was obtained from what
was labelled in chart review and not based on serum markers.
Menopausal status was more clearly specified in the diagnosis
history and physical notes but at 1 year was only mentioned clearly
in some patients’ charts and in other cases postmenopausal status
BRITISH JOURNAL OF CANCER Predictors of weight gain in breast cancer patients
874 www.bjcancer.com|DOI:10.1038/bjc.2013.441was inferred from descriptions of no menses for 41 year. Given
the lack of thorough charting in follow-up notes, approximately
10% of 1-year data on menopausal status are missing, as can be
seen in Table 1. No statistically significant differences in weight
gain were seen at any time points for radiation therapy, family
history, HER2 status, or menopausal status at 1 year.
Single SNP analysis. Single SNP analyses were conducted using a
generalised linear model with effect sizes and quartile analyses with
ORs, adjusting for clinical covariates. Results are as shown in
Table 4. One FTO SNP (rs7206790) and six adiponectin pathway
SNPs (rs1342387, rs822396, rs2232853, rs1501299, rs7539542, and
rs10920531) were found through additive or dominance effects to
be associated with weight gain for at least one time point, with the
adiponectin rs822396 SNP through additive effects being the only
one to show significance at two time points.
Multivariate analysis. We used the Bayesian hierarchical generalised
linear model for our multivariate analysis. This was performed
using both epistatic and non-epistatic models as well as models
including the FTO SNPs alone, the adiponectin pathway SNPs
alone, and a combination of both sets of SNPs. The epistatic model
using both sets of SNPs showed the best fit with smallest deviance
and so was chosen to interpret our results as shown in Table 5.
Also included are the results of multivariate quartile analysis.
Paying particular attention to the SNPs that are significant at the
12-month or final 18-month points either individually or part of an
interaction, rs822396, rs266729, rs1342387, and rs7539542 are
notable. For the clinical variables, age and BMI were again
significant across multiple time points (though age lost significance
Table 1. Baseline characteristics of 459 patients
Mean (range)
Age (years) 51.3 (26–84)
BMI at diagnosis (kgm
–2) 27.5 (14.9–51.9)
Weight at diagnosis (kg) 74.2 (36.4–144.1)
N (%)
Race
Caucasian 342 (74.5)
African American 68 (14.8)
Asian 22 (4.8)
Hispanic 20 (4.4)
Unknown 7 (1.5)
Stage at diagnosis
I 158 (34.4)
II 194 (42.3)
III 106 (23.1)
Unknown 1 (o0.1)
Lymph node metastases
þ 232 (50.5)
  217 (47.3)
Unknown 10 (2.2)
Tumour grade
1 84 (18.3)
2 196 (42.7)
3 163 (35.5)
Unknown 16 (3.5)
ER status
þ 367 (80.0)
  92 (20.0)
PR status
þ 323 (70.4)
  132 (28.8)
Unknown 4 (0.9)
Her2 status
þ 78 (17.0)
  366 (79.7)
Unknown 14 (3.3)
Menopause at diagnosis
Premenopausal 222 (48.4)
Perimenopausal 22 (4.8)
Postmenopausal 204 (44.4)
Unknown 11 (2.4)
Menopause at 1 year
Premenopausal 112 (24.4)
Perimenopausal 31 (6.8)
Postmenopausal 272 (59.3)
Unknown 44 (9.6)
Family history
þ 194 (42.3)
  254 (55.3)
Unknown 11 (2.4)
Abbreviation: BMI¼body mass index; ; ER = estrogen receptor; PR = progesterone
receptor.
Table 2. Baseline treatment characteristics
N (%)
Radiation
þ 322 (70.2)
  131 (28.5)
Unknown 6 (1.3)
Chemotherapy
þ 325 (70.8)
  134 (29.2)
Type of chemotherapy
AC 4 66 (20.3)
TC 4 23 (7.1)
Anthracycline þ taxane chemotherapy
a 194 (59.7)
Other
b 42 (12.9)
Endocrine therapy
þ 359 (78.2)
  99 (21.6)
Unknown 1 (0.2)
Type of endocrine therapy
Tamoxifen 5 years 150 (41.8)
Aromatase inhibitor 5 years 134 (37.3)
Tamoxifen 5 years followed by aromatase inhibitor 72 (20.1)
Unknown or other 9 (2.5)
Abbreviations: AC¼adriamycin/cyclophosphamide; TC¼taxotere/cyclophosphamide.
aIncludes AC, then taxol (T)  8, AC then T weekly, dose dense ACT, taxotere/AC, and AC
then T þ herceptin.
bIncludes lapatinib, lapatinib/abraxane, lapatinib/abraxane/herceptin, cyclophosphamide/
doxorubicin/5-fluorouracil, 5-fluorouracil/epirubicin/cyclophosphamide, taxotere/navelbine,
taxol alone, carboplatin-taxotere, herceptin.
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risk for weight gain, consistent with our univariate analysis.
Oestrogen receptor status positivity, absence of chemotherapy, and
lower stage were also associated with increased weight gain,
although stage was only significant at the 6-month time point.
Predictive models. We created several clinical, genetic, and
combination models using the above data to predict the post-
diagnosis weight gain in our patients. As described in the Materials
and Methods section, discriminatory power of our predictive
models was assessed by performing ROC analysis (Figure 1). The
ROC curves show the estimated true-positive and the false-positive
rates for different classification thresholds between 0 and 1. The
AUC represents the probability that given two random individuals,
one who will develop the disease and the other who will not, the
predictive model will assign the former as a positive test and the
latter as a negative test. A perfect predictive model would have an
AUC of 1. It has been suggested that an AUC40.5 has some
discriminatory ability and for screening high-risk individuals an
AUC40.75 should be used (Janssens et al, 2007).
A traditional clinical model was generated with the significant
variables on univariate analysis and yielded AUCs of 0.51, 0.50,
and 0.47 for 6, 12, and 18-month weight gains, respectively. For the
genetic SNP models, analyses were conducted on both main effect
and epistatic models for FTO SNPs alone, adiponectin pathway
SNPs alone, and the combination of both at each time point. We
performed the analyses first by focusing on only the significant
SNPs seen in the above multivariate analysis and then by including
all the SNPs. We found that an epistatic model incorporating all 14
SNPs had highest AUCs with values of 0.84, 0.81, and 0.79 for 6,
12, and 18-month weight gains, respectively. In comparison, the
epistatic model incorporating only significant SNPs had AUCs of
0.57, 0.59, and 0.24 and the main effects model with all 14 SNPs
had AUCs of 0.6, 0.6, and 0.59. Incorporating both FTO and
adiponectin pathway SNPs yielded higher AUC values than
including only one of these groups. Using our most predictive
model of all 14 SNPs and their epistatic interactions, we analysed
several combinations with clinical variables and found that
incorporating all significant clinical variables decreased the AUCs
to values of 0.55, 0.48, and 0.52. In contrast, addition of only the
baseline age and BMI yielded our most powerful model, as
illustrated in Figure 1, with AUC values of 0.90, 0.88, and 0.85, for
6, 12, and 18-month weight gains, respectively.
DISCUSSION
Using a retrospective cohort analysis of 459 breast cancer patients,
we were able to construct a primarily SNP-based predictive model
with high discriminatory power for post-diagnosis weight gain. We
tested multiple predictive models, including a traditional clinical
model, genetic model using FTO and adiponectin pathway SNPs,
and combination models, and we found that a model incorporating
all 14 SNPs (from FTO, ADIPOQ, and ADIPOR1) studied in
addition to their epistatic interactions and baseline age and BMI
was most predictive of weight gain with AUC as high as 0.90 for 6-
month weight gain and 0.85 for 18-month weight gain.
In creating these models, we initially evaluated for specific
polymorphisms±epistatic interactions with significant associa-
tions to weight gain as highlighted in Tables 4 and 5. Notably,
rs822396 (ADIPOQ) was statistically significant across our
different genetic analyses presented – linear univariate analysis,
multivariate analysis, and quartile analyses. We previously showed
this polymorphism contributes to risk of prostate and colon cancer
and other groups have shown increased risk of type 2 diabetes and
ischaemic stroke (Hegener et al, 2006; Kaklamani et al, 2008b,
2011b; Mtiraoui et al, 2012), but this is the first published
correlation to post-diagnosis weight gain in breast cancer patients.
The other SNPs listed in the multivariate analysis were less
consistently significant across different analyses and time points.
Table 3. Weight changes in patient population
6 Months 12 Months 18 Months
Average BMI (weight) change 0.07kgm
–2 (0.3kg) 0.32kgm
–2 (1.0kg) 0.56kgm
–2 (1.9kg)
% Of patients with 40.5kgm
–2 m BMI 33.0% 49.0% 56.0%
Average BMI (weight) increase
a 1.3kgm
–2 (3.5kg) 1.6kgm
–2 (4.4kg) 1.9kgm
–2 (5.1kg)
% Of patients with 4 5% m BMI 13.0% 27.0% 36.0%
Average BMI (weight) increase
b 2.0kgm
–2 (5.5kg) 2.3kgm
–2 (6.1kg) 2.5kgm
–2 (6.7kg)
Maximum BMI % m 18.0% 31.0% 38.0%
Maximum BMI (weight) m 5.0kgm
–2 (15.1kg) 6.4kgm
–2 (16.5kg) 9.0kgm
–2 (23.5kg)
Abbreviation: BMI¼body mass index.
aAmong patients with 40.5kgm
–2 m BMI.
bAmong patients with 45% m BMI.
Table 4. Significant SNPs in single SNP analyses
a,b
6 Months
(effect size
c)
12 Months
(effect size)
18 Months
(effect size)
ADIPOQ rs822396a 0.186** 0.208**
ADIPOR1 rs2232853d 0.122*
ADIPOQ rs1501299a  0.108*
FTO rs7206790d  0.112*
ADIPOR1 rs7539542a  0.114**
ADIPOR1 rs7539542d 0.117*
ADIPOR1 rs10920531a  0.077*
Abbreviations: BMI¼body mass index; SNP¼single-nucleotide polymorphism. *Po0.05,
**Po0.01.
aAdjusted for significant clinical variables in descriptive analysis: at 6 months for BMI at
diagnosis, age, race, stage, lymph node metastases, estrogen receptor status, progesterone
receptor status, chemotherapy, and hormone therapy; at 1 year for BMI at diagnosis, age,
stage, estrogen receptor status, menopause status at diagnosis, chemotherapy, and hormone
therapy; at 18 months for BMI at diagnosis, race, estrogen receptor status, menopause status
at diagnosis, menopause transition from pre to postmenopausal at 1 year, and hormone
therapy. Quartile analyses were adjusted for all clinical variables at each time point.
bNo significant findings on quartile analysis.
cEffect size defined as difference in BMI gain with presence of the variable of interest. Positive
values denote relative increase in BMI gain by that quantity. Negative values denote relative
decrease in BMI gain by that quantity.
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6 Months
(effect size
a)
12 Months
(effect size)
18 Months
(effect size)
Quartile analysis
b
at 6 months (OR)
Quartile analysis at
12 months (OR)
Quartile analysis
at 18 months (OR)
Age  0.144*  0.110**
BMI at diagnosis  0.083*  0.140**
Stages II vs III 0.117*
Chemotherapy  0.179**  0.097*
ER positive 0.223* 0.134** 0.224**
Grades 2 vs 3 0.158*
rs7206790a  0.082*
rs8047395a 0.078*
rs1501299a  0.112**
rs10920531a rs822396a  0.100**
rs12733285d rs1501299a  0.228**
rs12733285d rs9939609d  0.314**
rs1342387d  0.104**
rs266729d  0.994**
rs1342387d rs266729d  0.209**
rs266729d rs7539542d 0.466**
rs822396a 0.236*
Abbreviations: BMI¼body mass index; ER = estrogen receptor; OR¼odds ratio.
*Po0.05, **Po0.01.
aEffect size defined as difference in BMI gain with presence of the variable of interest. Positive values denote relative increase in BMI gain by that quantity. Negative values denote relative
decrease in BMI gain by that quantity.
bQuartile cutoffs were p 0.54kgm
–2 and X0.73kgm
–2 at 6 months, p 0.40 kgm
–2 and X1.20kgm
–2 at 12 months, and p 0.22kgm
–2 and X1.64kgm
–2 at 18 months for lower (p25%)
and higher quartiles (X75%), respectively.
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Figure 1. ROC curves at 6, 12, and 18 months. Solid line indicates ROC curve for the significant clinical variable model (AUC¼0.51 at 6 months,
0.50 at 12 months, and 0.47 at 18 months), dashed line indicates ROC curve for the 14 SNPs model (AUC¼0.60 at 6 months, 0.59 at 12 months,
and 0.58 at 18 months), and dotted line indicates ROC curve for the 14 SNPsþepistatic interactionsþageþBMI at diagnosis model (AUC¼0.90
at 6 months, 0.88 at 12 months, and 0.85 at 18 months). The grey line represents AUC of 0.5.
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or 18-month time points were interactions among rs266729
(ADIPOQ), rs1342387 (ADIPOR1), and rs7539542 (ADIPOR1).
In addition to also having associations with risk of prostate and
colon cancer, type 2 diabetes, and ischaemic stroke, these SNPs
have been linked to coronary artery disease, hypertension, and
efficacy of weight loss products such as sibutramine (Hegener et al,
2006; Siitonen et al, 2006; Kaklamani et al, 2008b; Hsiao et al, 2010;
Han et al, 2011; He et al, 2011; Liu et al, 2011; Kaklamani et al,
2011b; Mather et al, 2012; Mtiraoui et al, 2012; Yang et al, 2012;
Zhang et al, 2012). Receiver operating characteristic analysis of an
epistatic model of significant SNPs on multivariate analysis only
showed AUC of 0.24 for 18-month weight gain. When the models
were expanded to include all 14 SNPs, this value increased to
0.79, highlighting the loss of discriminatory power with limiting
analysis to only selected SNPs; of note, analysis with only the 10
adiponectin pathway SNPs or the 4 FTO SNPs yielded lower AUC
values as well.
To create a clinical predictive model and isolate variables for a
combined genetic and clinical model, we assessed various
demographic and clinical variables. We found that younger
patients and those with lower BMI at diagnosis are more likely
to gain weight, which is consistent with other studies (Rock and
Demark-Wahnefried, 2002; Irwin et al, 2005; Kroenke et al, 2005;
Caan et al, 2006; Saquib et al, 2007; Gu et al, 2010). Although there
was a general trend that Hispanics gained more weight than whites
who gained more weight than Asians and African Americans, this
was not shown to be significant in our analyses.
In terms of treatment factors, chemotherapy was actually
associated with decreased weight gain in multivariate analysis at
6- and 12-month time points and lost significance at the final
18-month time point. Historically, chemotherapy has been thought
to contribute to weight gain as seen in many prior studies (Rock
and Demark-Wahnefried, 2002; Kroenke et al, 2005; Caan et al,
2006; Saquib et al, 2007; Heideman et al, 2009; Gu et al, 2010).
Several studies have contradicted this and proposed that the
shorter duration regimens that are now used such as TC regimens
do not cause this weight gain (Demark-Wahnefried et al, 1997a;
Kutynec et al, 1999; Freedman et al, 2004; Ingram and Brown,
2004). As seen in Table 1, the majority of our patients received
adriamycin/cyclophosphamide, TC, or ddACT regimens as
opposed to the longer FEC and CMF regimens, which are included
in the ‘other’ category.
Effect of menopausal status has been conflicting in the literature
with the majority of reports showing increased weight gain with
premenopausal status (Camoriano et al, 1990; Rock and Demark-
Wahnefried, 2002; Caan et al, 2006; Campbell et al, 2007;
Heideman et al, 2009) or absence of effect (Aslani et al, 1999;
Costa et al, 2002; Lankester et al, 2002; Han et al, 2009) and the
minority showing weight gain with postmenopausal status (Irwin
et al, 2005). Our study showed premenopausal status at diagnosis
was associated with weight gain in univariate analysis but after
adjusting for other significant clinical variables as well as SNPs,
found no significant difference. Consistent with some other
studies, we showed that the subset of patients who underwent
transition from premenopausal status at diagnosis to postmeno-
pausal at 1 year gained weight (Goodwin et al, 1999; Campbell
et al, 2007) although this too lost significance in multivariate
analysis. It is important to mention that the menopausal status was
gathered from chart review and was not based on objective
evaluation. This chart review process likely decreased the accuracy
of menopausal status categorisation, in particular decreasing the
frequency of patients assigned as ‘postmenopausal’ at 1 year or
‘perimenopausal’ at either time point. It is possible that this limited
our power to find a relationship between premenopausal
to postmenopausal transition at 1 year and post-diagnosis
weight gain.
With respect to tumour characteristics, our study interestingly
found that oestrogen receptor positivity was found to be associated
with weight gain at each time point in both the univariate and
multivariate analyses. This association has only been weakly
demonstrated in the literature (Goodwin et al, 1999) with most
studies finding no correlation (Camoriano et al, 1990; Han et al,
2009; Gu et al, 2010). Further studies will need to continue
exploring hormone receptor status as a causative factor. We did
not find strong consistent correlations for other tumour
characteristics. Lower stage tumours were associated with weight
gain at 6 months but lost significance by 12 months and lymph
node metastases were not found to be significant at any time point.
Similarly, low-grade tumours were only significant at 18 months by
quartile analysis, which is a less robust statistical analysis than the
linear model using effect sizes. More of the literature supports
weight gain with higher stage tumours (Demark-Wahnefried et al,
1997b; Goodwin et al, 1999; Irwin et al, 2005; Gu et al, 2010)
but there is also contradictory literature (Rock and Demark-
Wahnefried, 2002; Kroenke et al, 2005).
We created a predictive clinical model incorporating significant
findings and found an AUC of only 0.47 at 18-month time point,
indicating the generally low discriminatory ability of the clinical
variables and perhaps explaining the conflicting findings in the
literature for the majority of these variables. We also created
combination models with the 14 SNPs and their epistatic
interactions as the base and found that adding all the significant
covariates decreased the AUC from 0.79 at 18 months to 0.52.
The model, however, was enhanced by adding only baseline age
and BMI with resulting AUC of 0.85. This combination model
of 4 FTO SNPsþ10 adiponectin pathway SNPsþepistatic
interactionsþbaseline ageþbaseline BMI was therefore our
optimal model with highest predictive power.
Our study has several strengths and limitations. One limitation
of this retrospective cohort study is that the weights were obtained
by chart review. However, although weight was not measured on a
standardised scale at each visit, it was still measured during clinic
visits as opposed to via patient self-reporting, so it is unclear how
much this affected the results if at all. We excluded weight data that
were not within 2 months of our desired time points, thereby
maximising accuracy of our measurements. We are currently
conducting a prospective study of 300 breast cancer patients who
will be weighed at 6-month intervals in a controlled setting to
better address this limitation. As mentioned above, menopausal
status, especially at 1 year, may also have been inaccurate because
of the retrospective nature of this study. Another limitation is that
the study design did not have a control group of matched non-
breast cancer patients to compare weight gain trends and the
predictive role of the polymorphisms and clinical variables studied.
Although this data would have been interesting, it is not clinically
relevant as post-breast cancer diagnosis weight gain, irrespective of
what proportion is secondary to the breast cancer diagnosis and
subsequent treatments, is associated with poor outcomes and needs
to be minimised. The median age of our patients is lower than that
of the United States (Gloeckler Ries et al, 2003). However, previous
published work from our group includes patients of similar
demographics (Kaklamani et al, 2008a; Kaklamani et al, 2011a)
depicting the patient population seen in our centre. We do not
believe that this impacts on our results. The strengths of our study
are the large number of patients included in the cohort and the
combination analysis of clinical and genetic characteristics.
This is the first study to evaluate the effects of genetic
polymorphisms as well as their gene environment interactions
on post-diagnosis weight gain in breast cancer patients. Our final
model shows high discriminatory power with AUCs of 0.90, 0.88,
and 0.85 for weight gain at 6, 12, and 18 months post-diagnosis,
respectively. We are currently conducting a prospective
study of 300 newly diagnosed breast cancer patients to validate
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identify patients at highest risk for weight gain and target them for
weight loss interventions starting at the time of diagnosis.
Numerous interventions have been published for this patient
population, including diet (De Waard et al, 1993; Loprinzi et al,
1996; Jen et al, 2004; Chlebowski et al, 2006; Hoy et al, 2009),
exercise (Schwartz, 2000; Segal et al, 2001), and multidisciplinary
(Goodwin et al, 1998; Campbell et al, 2012; Harris et al, 2012)
approaches with mixed results and limited long-term data on
sustained weight loss. In addition, wide spread implementation of
weight loss intervention is less feasible than in a limited
population. With a targeted population, the interventions can be
more effective, future clinical trials more efficient, and resources
more intelligently appropriated. We hope this strategic approach
will more effectively prevent the post-diagnosis weight gain seen in
breast cancer patients and thereby decrease the associated
morbidity and mortality.
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